The Clinical Epidemiology of Scrub Typhus in Humans, Chiggers and Rodents
NCT ID: NCT02876367
Last Updated: 2021-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1200 participants
OBSERVATIONAL
2016-09-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Scrub Typhus RDT Study
NCT03269266
Rickettsia Clearance Study
NCT05972772
Eschar Investigations in Scrub Typhus
NCT02915861
Scrub Typhus Infection Induced Cardiovascular Disease
NCT03274869
Scrub Typhus Antibiotic Resistance Trial
NCT03083197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The project will undertake a detailed investigation of one human community, and its environment, at risk of scrub typhus:
Chiggers, Rodents \& Habitat Study:
Transects across diverse habitats determining spatial distribution of species of chiggers and rodents. This will be performed 3x/year.
High-resolution habitat mapping. Comparison of genomes of O. tsutsugamushi detected in different environments, using attempted WGS.
Village Cohort Study:
Follow a cohort of villagers over 2 years screening all febrile patients for scrub typhus and determining seroconversion rates and infecting O. tsutsugamushi genotypes.
Procedures:
* Mites:
Working with ecology/GIS collaborators, the environment of the community will be mapped and transects laid across the diverse habitats used by the community. Free-living mites will be collected with black plastic plates and black cloth21, from soil using Berlese funnels and from rodents. Trombiculid mites will be identified to genus and a subset to species.
DNA will be extracted from individual chiggers, and qPCR screening for O. tsutsugamushi-positivity performed (real-time PCR targeting 47kDa-gene). A proportion of confirmed positives will undergo genotyping by attempted whole-genome sequencing (WGS).
* Rodents:
Rodents will be captured alive along transects and identified in collaboration with University of Montpellier24. All mites will be removed from rodents, the rodents killed and the rodent spleen and liver collected for O. tsutsugamushi qPCR screening. A proportion of O. tsutsugamushi-positive samples will undergo genotyping by attempted WGS or extended MLST analysis.
* Human cohort:
All those in the community (\>10 years old) will be approached and asked for consent to participate. All enrolled will have scrub typhus ELISA/IFA (from finger-prick filter paper blood spots) performed every 4 months over 2 years to estimate the rates and dynamics of seroconversion. A brief questionnaire will be administered at each visit to determine whether the participant had a febrile illness in the preceding 4 months.
Patients presenting with a febrile illness to local healthcare facilities will be clinically assessed and an on-site scrub typhus IgM rapid diagnostic test (RDT) performed. RDT positive patients will be recruited into the study, and paired acute/convalescent samples sent to LOMWRU for ELISA, qPCR and BSL3 culture, followed by genotyping by attempted WGS. A questionnaire will be administered to recruited patients to determine symptomatology and vital signs recorded.
Epidemiology \& Ecology:
The exact sample collection locations and habitat details will be recorded.
Genomic analyses:
To characterize the relationships between highly diverse O. tsutsugamushi genotypes in multiple strain/genotype-infected hosts a proportion of qPCR positives (approx. 480 samples) will be analysed by whole-genome sequencing at WTCHG in Oxford.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute scrub typhus (Group 1)
Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using \<1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
No interventions assigned to this group
Scrub typhus serosurvey (Group 2)
Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Presenting with fever \>38 C and testing positive by scrub typhus RDT.
2. Male or Female, aged 10 years or above.
3. Participant is willing and able to give informed consent for participation in the study.
Scrub typhus serosurvey (Group 2)
1. Villagers living in an environment in which scrub typhus is known to be present, who are asymptomatic.
2. Male or Female, aged 10 years or above.
3. Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria
1. Villagers/patients under 10 years of age.
2. Those unwilling to give written informed consent.
Scrub typhus serosurvey (Group 2)
1. Villagers/patients under 10 years of age.
2. Those unwilling to give written informed consent.
10 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahidol Oxford Tropical Medicine Research Unit
OTHER
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
OTHER
Wellcome Trust
OTHER
Centre National de la Recherche Scientifique, France
OTHER
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OxTREC no. 48-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.